US4956355A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Agents for the arrest and therapy of retroviral infections
Assignee: HARBOR DIVERSIFIED Inc
•
Filing: 1988-04-15
•
Granted: 1990-09-11
•
Expires: 2008-04-15
Abstract
Abstract Compounds of the general Formula (I) ##STR1## in which R is a hydrogen atom or a bromine atom, and R 1 is a hydrogen atom, an SO 2 OM group wherein M is a hydrogen or sodium atom, various sulphatide or phosphatide groups or a glucuronide group are disclosed for use in the prophylaxis and therapy of retroviral infections, especially infection by Human Immunodeficiency Virus. These compounds may be used concomitantly or in combination with various immunomodulators and/or antiviral agents.
Inventors
- 👤 Patrick T. Prendergast
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-11-06 12:18
CPC Classifications
C; C07; C07J; C07J51/00; A; A61; A61K; A61K31/00; A61K31/56; A61K31/565; A61K31/66; A61K31/70; A61K31/715; A61K36/00; A61K36/18; A61K36/185; A61K36/25; A61K36/258; A61K39/00; A61K39/395; A61K39/39533; A61K45/00; A61K45/06; A61P; A61P31/00; A61P31/12; A61P31/14; A61P31/18; C07J31/00; C07J31/006; A61K38/00
Claims Analysis
Total Claims: 18
Claim 1
Independent Claim
205 words
A method for treating or arresting the progression of a retroviral infection in a patient in need of such treatment which comprises administering to said patient A therapeutically effective amount of a compound of the formula (I). ##STR6## in which R is selected from the group consisting of a hydrogen atom and a bromine atom, and R 1 is a chemical group selected from the group consisting of a hydrogen atom, an SO 2 OM group wherein M is selected from the group consisting of a hydrogen atom, a sodium atom, a sulphatide group ##STR7## ##STR8## wherein each of R 2 and R 3 , which may be the same or different, is selected from the group consisting of straight and branched chain alkyl radicals of 1 to 14 carbon atoms, a phosphatide group ##STR9## wherein each of R 2 and R 3 , which may be the same or different, is selected from the group consisting of straight and branched chain alkyl radicals of 1 to 14 carbon atoms, and a glucoronide group ##STR10## wherein the broken line represents an optical double bond, and the hydrogen atom at position 5 is present in the α- or β -configuration or a mixture of both configurations.
Claim 2
Independent Claim
205 words
A method for treating or arresting the progression of a retroviral infection in a patient in need of such treatment which comprises administering to said patient A therapeutically effective amount of a compound of the formula (I). ##STR6## in which R is selected from the group consisting of a hydrogen atom and a bromine atom, and R 1 is a chemical group selected from the group consisting of a hydrogen atom, an SO 2 OM group wherein M is selected from the group consisting of a hydrogen atom, a sodium atom, a sulphatide group ##STR7## ##STR8## wherein each of R 2 and R 3 , which may be the same or different, is selected from the group consisting of straight and branched chain alkyl radicals of 1 to 14 carbon atoms, a phosphatide group ##STR9## wherein each of R 2 and R 3 , which may be the same or different, is selected from the group consisting of straight and branched chain alkyl radicals of 1 to 14 carbon atoms, and a glucoronide group ##STR10## wherein the broken line represents an optical double bond, and the hydrogen atom at position 5 is present in the α- or β -configuration or a mixture of both configurations.
Claim 3
Independent Claim
20 words
A method according to claim wherein in the compound of the formula (I) R and R 1 are each hydrogen.
Claim 4
Dependent Claim
27 words
A method according to claim 2, wherein the compound is dehydroepiandrosterone, the compound wherein R and R 1 are each hydrogen and the double bond is present.
Claim 5
Dependent Claim
27 words
A method according to claim 1, wherein the compound is 16α-bromoepiandrosterone, the compound wherein R is bromine, R 1 is hydrogen and the double bond is present.
Claim 6
Dependent Claim
12 words
A method according to claim 1, wherein the compound is dehydroepiandrosterone sulphate.
Claim 7
Dependent Claim
17 words
A method according to claim 1, wherein the compound of formula (I) is formulated for systemic administration.
Claim 8
Dependent Claim
22 words
A method according to claim 1, wherein the compound of the formula (I) is administered concomitantly or in combination with an immunomodulator.
Claim 9
Dependent Claim
24 words
A method according to claim 1, wherein the compound of the general formula (I) is administered concomitantly or in combination with an antiviral agent.
Claim 10
Dependent Claim
16 words
A method according to claim 1 wherein the retroviral infection is a Human Immunodeficiency Virus Infection.
Claim 11
Dependent Claim
17 words
A method according to claim 1 wherein the retroviral infection has progressed to Acquired Immunodeficiency Syndrome (AIDS).
Claim 12
Dependent Claim
22 words
A method according to claim 10, wherein the compound of the Formula (I) is administered concomitantly, or in combination with an immunomodulator.
Claim 13
Dependent Claim
23 words
A method according to claim 10, wherein the compound of the Formula (I) is administered concomitantly or in combination with an antiviral agent.
Claim 14
Dependent Claim
19 words
A method according to claim 1 wherein the retroviral infection has progressed to Acquired Immunodeficiency Syndrome Related Complex (ARC).
Claim 15
Dependent Claim
21 words
A method according to claim 13, wherein the compound of Formula (I) is administered concomitantly or in combination with an immunomodulator.
Claim 16
Dependent Claim
23 words
A method according to claim 13, wherein the compound of the Formula (I) is administered concomitantly or in combination with an antiviral agent.
Claim 17
Independent Claim
200 words
A method for the treatment of a patient who has a retroviral infection, which comprises administering to said patient a prophylactically or therapeutically effective amount of a compound of the formula (I) ##STR11## in which R is selected from the group consisting of a hydrogen atom and a bromine atom, and R 1 is a chemical group selected from the group consisting of a hydrogen atom, an SO 2 OM group wherein M is selected from the group consisting of a hydrogen atom, a sodium atom, a sulphatide group ##STR12## ##STR13## wherein each of R 2 and R 3 , which may be the same or different, is selected from the group consisting of straight and branched chain alkyl radicals of 1 to 14 carbon atoms, a phosphatide group ##STR14## wherein each of R 2 and R 3 , which may be the same or different, is selected from the group consisting of straight and branched chain alkyl radicals of 1 to 14 carbon atoms, and a glucuronide group ##STR15## wherein the broken line represents an optical double bond, and the hydrogen atom at position 5 is present in the α- or β -configuration or a mixture of both configurations.
Claim 18
Independent Claim
200 words
A method for the treatment of a patient who has a retroviral infection, which comprises administering to said patient a prophylactically or therapeutically effective amount of a compound of the formula (I) ##STR11## in which R is selected from the group consisting of a hydrogen atom and a bromine atom, and R 1 is a chemical group selected from the group consisting of a hydrogen atom, an SO 2 OM group wherein M is selected from the group consisting of a hydrogen atom, a sodium atom, a sulphatide group ##STR12## ##STR13## wherein each of R 2 and R 3 , which may be the same or different, is selected from the group consisting of straight and branched chain alkyl radicals of 1 to 14 carbon atoms, a phosphatide group ##STR14## wherein each of R 2 and R 3 , which may be the same or different, is selected from the group consisting of straight and branched chain alkyl radicals of 1 to 14 carbon atoms, and a glucuronide group ##STR15## wherein the broken line represents an optical double bond, and the hydrogen atom at position 5 is present in the α- or β -configuration or a mixture of both configurations.
References Cited (Backward Citations)
US4005200A
Cited
US4518595A
Cited
EP0133995A2
Cited
US4602008A
Cited
US4724232A
Cited
US4628052A
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1993-09-10 | 1994-03-12 | 1994-09-11 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1997-09-10 | 1998-03-12 | 1998-09-11 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 2001-09-10 | 2002-03-12 | 2002-09-11 | $7700.00 | Window Closed / Lapsed |